Layer, Chiang, et al. Genome Biology
Novartis Options Quark's Phase II p53 Inhibitor
The agreement comes as Quark weighs going public on the Tel-Aviv Stock Exchange, a move a company official said would position the firm to meet its ultimate goal of floating its shares on the Nasdaq.
New to GenomeWeb? Register here quickly.